Luigi Nocera
Vita-Salute San Raffaele University
EpidemiologyCancerInternal medicineRadiologyUrologyEthnic groupOncologyLogistic regressionStage (cooking)Hazard ratioProstatectomyProstate cancerIn patientProportional hazards modelMedicineCumulative incidence
89Publications
8H-index
191Citations
Publications 104
Newest
#1Marina Kosiba (UdeM: Université de Montréal)
#2L. Franziska Stolzenbach (UdeM: Université de Montréal)H-Index: 5
Last. Pierre I. Karakiewicz (UdeM: Université de Montréal)H-Index: 119
view all 14 authors...
Abstract null null Objective null To test 1) contemporary pelvic lymph node dissection (PLND) trends at radical cystectomy (RC) in variant histology bladder cancer (VHBC) patients and urothelial carcinoma of the urinary bladder (UCUB), as well as 2) to test the effect of PLND extent on cancer specific mortality (CSM) after RC. null null null Methods null Within the Surveillance, Epidemiology and End Results Registry (SEER, 2004–2016), we identified non-metastatic stage T1-2 or T3-4 VHBC and UCUB...
Source
#1M. Wenzel (UdeM: Université de Montréal)H-Index: 8
#2Claudia Collà Ruvolo (UdeM: Université de Montréal)H-Index: 8
Last. Pierre I. Karakiewicz (UdeM: Université de Montréal)H-Index: 119
view all 14 authors...
BACKGROUND The survival benefit of primary external beam radiation therapy (EBRT) has never been formally tested in elderly men who were newly diagnosed with metastatic prostate cancer (mPCa). We hypothesized that elderly patients may not benefit of EBRT to the extent as younger newly diagnosed mPCa patients, due to shorter life expectancy. METHODS We relied on Surveillance, Epidemiology and End Results (2004-2016) to identify elderly newly diagnosed mPCa patients, aged >75 years. Kaplan-Meier, ...
Source
Background: To test the effect of the ten most common non-urological primary cancers (skin, rectal, colon, lymphoma, leukemia, pancreas, stomach, esophagus, liver, lung) on overall mortality (OM) after secondary prostate cancer (PCa). Material and Methods: Within the Surveillance, Epidemiology and End Results (SEER) database, patients with ten most common primary cancers and concomitant secondary PCa (diagnosed 2004-2016) were identified and were matched in 1:4 fashion (age, year at diagnosis, r...
Source
#2Luigi Nocera (UdeM: Université de Montréal)H-Index: 8
Last. Pierre I. Karakiewicz (UdeM: Université de Montréal)H-Index: 119
view all 6 authors...
Three first line, randomized phase III trials (Keynote 426, Checkmate 9ER and Checkmate 214) relied on predefined statistical criteria to validate the survival advantage of immuno-oncology (IO) based systemic treatment in metastatic renal cell carcinoma (mRCC) relative to Sunitinib. Within each of these three trials, a stratification according to prior nephrectomy was addressed in post-hoc progression free survival (PFS) and overall survival (OS) analyses.
Source
#1Claudia Collà Ruvolo (University of Naples Federico II)H-Index: 8
#2Luigi Nocera (UdeM: Université de Montréal)H-Index: 8
Last. Pierre I. Karakiewicz (UdeM: Université de Montréal)H-Index: 7
view all 13 authors...
Abstract Background Contemporary incidence and mortality rates of upper tract urothelial carcinoma (UTUC) are unavailable. Objective To describe contemporary UTUC incidence and mortality rates in the USA. Design, setting, and participants Within the Surveillance, Epidemiology and End Results (SEER) database (2004–2016), we identified 13 075 UTUC patients. Of all, 9208 (70.4%) harbored nonmetastatic UTUC and were treated with radical nephroureterectomy versus 1174 (9.0%) who harbored metastatic U...
Source
#8Alberto Briganti (UniSR: Vita-Salute San Raffaele University)H-Index: 99
#9Anil Kapoor (McMaster University)H-Index: 39
Last. Aly-Khan A. Lalani (McMaster University)H-Index: 16
view all 20 authors...
INTRODUCTION AND OBJECTIVE:Four recent first line clinical trials that leverage immune-oncology agents have demonstrated an overall survival benefit relative to sunitinib. However, formal network m...
Source
Objectives null To examine the effect of specific Asian ethnic subgroups on stage at presentation and cancer-specific mortality in non-metastatic upper tract urothelial carcinoma among North American upper tract urothelial carcinoma Asian patients treated with radical nephroureterectomy. null Methods null We relied on the Surveillance, Epidemiology and End Results database, from 2004 to 2016. Kaplan-Meier plots and multivariable Cox regression models predicting cancer-specific mortality were use...
Source
#1M. Wenzel (UdeM: Université de Montréal)H-Index: 8
Last. Pierre I. KarakiewiczH-Index: 119
view all 15 authors...
Source
Last. Zhe TianH-Index: 30
view all 19 authors...
Source
#1M. Wenzel (UdeM: Université de Montréal)H-Index: 8
#2Marina Deuker (UdeM: Université de Montréal)H-Index: 7
Last. Derya Tilki (UHH: University of Hamburg)H-Index: 60
view all 0 authors...
Abstract null null Background null The efficacy of tyrosine kinase inhibitor (TKI)-based therapy after previous immuno-oncology therapy (IO) failure has been addressed before. However, summary efficacy estimates have never been generated in these reports. We addressed this void. null null null Material and methods null We systematically examined TKI efficacy after IO-failure and generated weighted median progression-free survival (PFS) estimates for Pazopanib, Axitinib, Cabozantinib, Sunitinib. ...
Source
This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.